Overview
What is Multidisciplinary Association For Psychedelic Studies Inc?
The Multidisciplinary Association for Psychedelic Studies Inc, headquartered in San Jose, California, is a nonprofit organization dedicated to advancing medical research and education through the careful use of psychedelics. In 2022, MAPS spearheaded clinical trials investigating MDMA-assisted therapy for PTSD and supported regulatory activities in preparation for a new drug application submission to the FDA. These efforts included the second phase 3 trial that continued until April 2022, and the MAPS Public Benefit Corporation's enrollment in MT1 study comparing the effects of MDMA-assisted therapy and placebo. To ensure access to this investigational therapy if it is approved, MAPS began discussions with the American Medical Association and the Veterans Administration. They also provided public education through presentations, publications, and media interviews, reaching millions of people in 2022. The Zendo Project's psychedelic harm reduction program provided in-person services at events like Burning Man and trained volunteers to offer peer support services to over 600 individuals. MAPS, with 58 employees, is a research and educational organization committed to clinical research, honest public education, harm reduction, and advocacy.
Official website here: www.maps.org
What are the reviews and ratings of this charity?
Charity Navigator rating: 75% (Three-Star out of Four Stars)
The Multidisciplinary Association for Psychedelic Studies (MAPS) has garnered a Three-Star rating from Charity Navigator, reflecting a solid level of accountability and financial health. With a commitment to transparency, they have a fully independent board and have successfully avoided material diversion of assets. However, their program expense ratio is relatively low at 51.95%, indicating that a significant portion of their expenditures may not directly fund programs, which could be a concern for potential donors.
User reviews consistently highlight MAPS' pioneering role in advocating for the therapeutic potential of psychedelics, particularly in treating conditions like PTSD, depression, and addiction. Many supporters express gratitude for the life-changing impacts of their research and the community they've fostered. Positive testimonies emphasize their commitment to rigorous scientific studies and the hope they provide for alternative mental health treatments.
On the flip side, there are some criticisms regarding their operational processes, with a few individuals reporting negative experiences related to study qualification and communication. While these cases are outnumbered by positive feedback, they indicate a need for improvement in the organization's client engagement. Overall, MAPS is seen as both a trailblazer in psychedelic research and an organization in need of continued refinement in its outreach and operational efficiency.
This AI summary has been generated from information found on Charity Navigator and Great Nonprofits.
Is Multidisciplinary Association For Psychedelic Studies Inc legitimate?
Multidisciplinary Association For Psychedelic Studies Inc is a legitimate nonprofit organization registered as a 501(c)(3) entity. Multidisciplinary Association For Psychedelic Studies Inc submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
Heare are some key statistics you may want to consider:
Executive Compensation: $1,495,686
Professional Fundraising Fees: $0
Other Salaries and Wages: $3,313,401
For more financial information, click here
Official website here: www.maps.org
What is the mission statement of Multidisciplinary Association For Psychedelic Studies Inc?
The Multidisciplinary Association for Psychedelic Studies (MAPS) is a non-profit organization dedicated to advancing medical research and education surrounding the therapeutic uses of psychedelics and marijuana. MAPS pursues this mission through various means, including clinical trials, therapist training, public education, harm reduction, and advocacy. In 2022, MAPS sponsored clinical trials investigating MDMA-assisted therapy for PTSD and supported regulatory activities for the proposed New Drug Application (NDA) submission to the US Food and Drug Administration (FDA). Additionally, MAPS prepared clinical study reports for 17 of its sponsored clinical trials of MDMA-assisted therapy for PTSD in adults and healthy volunteers. To expand access to investigational therapy if it's approved, MAPS initiated discussions with the American Medical Association and the Veterans Administration. MAPS also engaged in public education by presenting at conferences, publishing bulletins, articles, and books, and providing interviews to various media outlets. MAPS' Zendo Project's psychedelic harm reduction program offered in-person services at events like Burning Man and trained volunteers to provide peer support to individuals experiencing challenging psychological experiences.
Official website here: www.maps.org
What is the revenue of Multidisciplinary Association For Psychedelic Studies Inc?
Multidisciplinary Association For Psychedelic Studies Inc's revenue in 2023 was $18,250,069.
Official website here: www.maps.org
Who are the executives of Multidisciplinary Association For Psychedelic Studies Inc and what are their salaries?
The average compensation at Multidisciplinary Association For Psychedelic Studies Inc during 2023 was $84,370. There are 57 employees and 350 volunteers at Multidisciplinary Association For Psychedelic Studies Inc.
Here are 18 key members and their salaries:
- Compensation: $174,600
- Related: $0
- Other: $8,996
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $158,119
- Related: $0
- Other: $33,076
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $208,574
- Related: $0
- Other: $23,596
- Compensation: $192,423
- Related: $0
- Other: $36,489
- Compensation: $229,473
- Related: $0
- Other: $18,823
- Compensation: $203,266
- Related: $0
- Other: $15,737
- Compensation: $162,230
- Related: $0
- Other: $30,284
- Compensation: $167,350
- Related: $0
- Other: $10,226
- Compensation: $150,443
- Related: $0
- Other: $2,518
- Compensation: $124,498
- Related: $0
- Other: $2,277
- Compensation: $124,480
- Related: $0
- Other: $1,569
- Compensation: $123,975
- Related: $0
- Other: $11,829
Official website here: www.maps.org
Where can I find the form 990 for Multidisciplinary Association For Psychedelic Studies Inc?
Multidisciplinary Association For Psychedelic Studies Inc's most recent form 990 was submitted in 2023 and can be accessed here.
Official website here: www.maps.org
Learn more at the official website: www.maps.org
Mission Statement of Multidisciplinary Association For Psychedelic Studies Inc
The Multidisciplinary Association for Psychedelic Studies Inc (MAPS) is a research and educational organization dedicated to developing medical, legal, and cultural contexts for the careful use of psychedelics and marijuana. MAPS' mission is to facilitate the exploration of these substances' therapeutic potential through clinical research, therapist training, public education, harm reduction, and advocacy.
MAPS has been at the forefront of psychedelic research, sponsoring clinical trials studying investigational MDMA-assisted therapy for PTSD. In 2022, the organization completed enrollment for a study comparing the effects of MDMA-assisted therapy and therapy with placebo on mood and psychological experience in people trained to practice investigational MDMA-assisted therapy. MAPS also initiated the preparation of clinical study reports for 17 MAPS-sponsored clinical trials of investigational MDMA-assisted therapy for the treatment of PTSD in adults and healthy volunteers. These efforts aim to pave the way for potential reimbursement for psychedelic-assisted therapies by discussing code development with the American Medical Association.
In addition to research, MAPS is committed to providing education through presentations at public conferences and webinars, publishing articles on websites and social media channels, and publishing books in the trade. In 2022, MAPS educated millions through media exposures in online, broadcast, and print publications, including NPR, CNN, NBC, CBS, ABC, TIME, and Newsweek. The organization's Zendo Project's psychedelic harm reduction program provided in-person services at Burning Man, training volunteers to offer peer support services to over 600 individuals having challenging psychological experiences. As MAPS continues to push for the acceptance and legalization of psychedelic therapies, it remains an influential force in shaping the future of this field.
Shop smarter and support your favorite cause with the Give Freely browser extension. Save money with coupons and donate to charity with a single click. Download now!
Impact
October, 2024
Multidisciplinary Association for Psychedelic Studies Inc (MAPS) significantly influences the landscape of mental health treatment and public education regarding psychedelics and related therapies. Through rigorous medical research, MAPS focuses on investigating the therapeutic potential of MDMA-assisted therapy for PTSD, conducting multiple clinical trials to gather data on its efficacy and safety. In collaboration with the FDA, these trials aim to inform a New Drug Application (NDA) submission, potentially revolutionizing treatment options for individuals suffering from PTSD.
In addition to clinical research, MAPS engages in comprehensive public education efforts. They have reached millions through various media platforms, ensuring dissemination of accurate information about psychedelics. Their educational outreach includes presentations, publications, and interviews with major news outlets, thus fostering a more informed public perspective on these substances.
MAPS also prioritizes harm reduction through initiatives like the Zendo Project, which provides support services at large events, helping individuals navigate challenging psychological experiences. Their commitment to advocacy further emphasizes the importance of developing legal and cultural contexts that support the responsible use of psychedelics.
Overall, MAPS plays a pivotal role in advancing our understanding of psychedelics in therapeutic settings, promoting public awareness, and establishing frameworks for the safe application of these substances in mental health care.
This information is meant to be a general summary of Multidisciplinary Association For Psychedelic Studies Inc. Please take the time to review official sources before making any decisions based upon the content provided here.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2023.
- Investment Income: $27,210
- Program Service Revenue: $493,020
- Gross Receipts: $18,437,832
Assets and Liabilities:
- Total Assets: $129,587,906
- Total Liabilities: $51,524,747
- Net Assets: $78,063,159
Want to help this charity, for free? You can click here to learn more about Give Freely
Programs
Programs are reported by nonprofits in their tax forms and are normally their tax-exempt activities.
EVENT AND CONFERENCE INCOME
Revenue
$229,684
EDUCATION
Revenue
$210,684
ADMIN FEES
Revenue
$52,652
Organization Details
Founding Year
1986
Principal Officer
Kris Lotlikar
Website
www.maps.orgNTEE Category
Code: H99Z - Medical research
If you are a representative of Multidisciplinary Association For Psychedelic Studies Inc and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.